Short Bowel Syndrome Pipeline Insight

DelveInsight’s, “Short Bowel Syndrome – Pipeline Insight, 2022,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Short Bowel Syndrome Understanding

Short Bowel Syndrome: Overview

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Consequently, individuals with short bowel syndrome often have a reduced ability to absorb nutrients such as fats, carbohydrates (sugars) vitamins, minerals, trace elements and fluids (malabsorption). The specific symptoms and severity of short bowel syndrome vary from one person to another. Diarrhea is common, often severe and can cause dehydration, which can even be life threatening. Short bowel syndrome can lead to malnutrition, unintended weight loss and additional symptoms may be due to the loss of essential vitamins and minerals. There is no cure, but the disorder usually can be treated effectively. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications.

 

"Short Bowel Syndrome - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided which includes the disease overview and Short Bowel Syndrome treatment guidelines. The assessment part of the report embraces, in depth Short Bowel Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Short Bowel Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Short Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Short Bowel Syndrome.

Short Bowel Syndrome Emerging Drugs Chapters

This segment of the Short Bowel Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Short Bowel Syndrome Emerging Drugs

 

Apraglutide: VectivBio AG

Apraglutide is an investigational drug being developed as a once-weekly treatment for patients who have SBS with intestinal failure (SBS-IF). It is a next-generation, long-acting, potent, synthetic GLP-2 analog that acts as a selective, full agonist of the GLP-2 receptor. Apraglutide is designed to enable patients to minimize the burden from PS by increasing intestinal absorption of fluids, calories and nutrients. Apraglutide has successfully completed phase II studies and is currently being evaluated in a pivotal phaseIII clinical trial. In January 2019, the Food and Drug Administration (FDA) has granted Orphan Drug designation to apraglutide (Therachon AG), an investigational treatment for short bowel syndrome (SBS).

 

Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2 analog in development for the treatment of SBS. It was granted orphan drug designation by the U.S. FDA and is currently being studied in Phase III clinical trials.

Further product details are provided in the report……..

Short Bowel Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Short Bowel Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Short Bowel Syndrome

There are approx. 7+ key companies which are developing the therapies for Short Bowel Syndrome. The companies which have their Short Bowel Syndrome drug candidates in the most advanced stage, i.e. phase III include, VectivBio AG.

Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Short Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Short Bowel Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Short Bowel Syndrome therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Short Bowel Syndrome drugs.

Short Bowel Syndrome Report Insights

  • Short Bowel Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Short Bowel Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Short Bowel Syndrome drugs?
  • How many Short Bowel Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Short Bowel Syndrome?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Short Bowel Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Short Bowel Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Short Bowel Syndrome: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Short Bowel Syndrome – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Short Bowel Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Short Bowel Syndrome Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Apraglutide: VectivBio AG

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Glepaglutide: Zealand Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Short Bowel Syndrome Key Companies

Short Bowel Syndrome Key Products

Short Bowel Syndrome- Unmet Needs

Short Bowel Syndrome- Market Drivers and Barriers

Short Bowel Syndrome- Future Perspectives and Conclusion

Short Bowel Syndrome Analyst Views

Short Bowel Syndrome Key Companies

Appendix

List of Table

Table 1: Total Products for Short Bowel Syndrome

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Short Bowel Syndrome

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Product

• VectivBio
• Zealand Pharma
• 9 Meters Biopharma
• Hanmi Pharmaceutical
• Adocia
• PhaseBio Pharmaceuticals
• Surrozen

 

Forward to Friend

Need A Quote